Ayush Ministry reviews development of global health intervention codes for traditional medicine systems

Posted on by Vividh Bharathi

New Delhi, May 27 (IANS) The Ministry of Ayush on Wednesday said it conducted a high-level review meeting and consultative discussions on the development of the International Classification of Health Interventions (ICHI) and National Health Intervention Codes (NHIC) for Ayurveda, Siddha and Unani (ASU) systems of medicine on May 25 and 26 in online mode.

The initiative follows the landmark Memorandum of Understanding (MoU) and Donor Agreement signed between the Ministry of Ayush and the World Health Organisation (WHO).

The objective is to create a globally standardised and scientifically robust coding vocabulary for ASU clinical interventions that can support cross-border data exchange, clinical research and interoperability in global healthcare systems, including insurance integration.

The meeting was chaired by Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush, who underlined the strategic importance of internationally aligned intervention classifications.

He said the initiative would help integrate traditional medicine systems into global healthcare frameworks, improve documentation practices and strengthen interoperability in digital health ecosystems.

The inaugural session began with welcome remarks by Dr. N. Srikanth, Deputy Director General of the Central Council for Research in Ayurvedic Sciences (CCRAS). Dr. Kavita Jain, Joint Secretary, Ministry of Ayush, highlighted the importance of standardised intervention terminology for strengthening evidence-based traditional medicine systems.

Representatives from the World Health Organization also participated in the discussions. Dr. Pawan Godatwar, Technical Officer at WHO South-East Asia Regional Office (SEARO), and Dr. Geetha Krishnan, Unit Head at GTMC Jamnagar, addressed the session and discussed the global relevance of standardized coding systems for traditional medicine.

Detailed technical presentations on the four-level hierarchical coding directories were delivered by the respective research councils.

Prof. Vaidya Rabinarayan Acharya, Director General of CCRAS, presented the Ayurveda coding framework (NHICA), while Prof. Dr. N. J. Muthukumar, Director General of CCRS, presented the Siddha intervention classification system (NHICS). Dr. N. Zaheer Ahmed, Director General of CCRUM, presented the Unani coding framework (NHICUM).

–IANS

pk

Related Posts

India sees over 30 pc decline in suicide death rates from 1990 to 2021: Lancet

New Delhi, Feb 20 (IANS) India has seen a more than 30 per cent reduction in the suicide death rate in India from 1990 to 2021, according to a study published in The Lancet Public Health on Thursday, marking a significant progress in health strategies.

The analysis, based on the results from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2021, showed that the suicide death rate in India was 18.9 per lakh population in 1990, in 2019 it stood at 13·1 lakh per lakh population and 13 per lakh population in 2021.

From 1990 to 2021, the suicide death rate in India declined to 31·5 per cent.

The reduction in death rates by suicide was seen more in females than males. In 1990 suicide death rate among females stood at 16·8 per lakh population, which reduced to 10·3 per lakh population in 2021.

On the other hand, the suicide death rate among men in 1990 stood at 20·9 per lakh population, and it reduced to 15·7 per lakh population by 2021.

“In 2020, in India, the highest suicide death rates were among educated women, with family problems being the most commonly cited contributing factor,” said the researchers from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, US.

Globally, the study showed about 740,000 suicides are reported annually, in other words, one person dies on average every 43 seconds by suicide.

However, in the last three decades, the global age-standardised mortality rate for suicide has declined by nearly 40 per cent — from about 15 deaths per lakh population to 9 deaths per lakh population. This indicates that intervention and prevention strategies are working.

For females, the rate declined by more than 50 per cent, while it declined by almost 34 per cent for males. Overall, the mortality rate for suicide was 12.8 per lakh population for males and 5.4 per lakh population for females.

“While the progress made in declining suicide rates is encouraging, it is clear that suicide continues to impact some countries and populations more than others. Removing suicide stigma and barriers to access mental health support systems remain critical measures, particularly among people with mental and substance abuse disorders,” said senior author Dr. Mohsen Naghavi with IHME.

–IANS

rvt/

India’s pharma, healthcare sector sees steady deal volumes as investors prefer scalable assets: Report

New Delhi, April 29 (IANS) India’s pharma and healthcare sector recorded 78 deals worth $1.9 billion in Q1 2026, with deal volumes holding steady even as overall values moderated in the absence of large‑ticket transactions, a report said on Wednesday.

The report from Grant Thornton Bharat said mergers and acquisitions accounted for 30 deals worth $915 million during the quarter, with volumes remaining broadly stable and values moderating about 40 per cent sequentially.

The moderation in the deals landscape was primarily driven by softer M&A values, even as private equity activity remained resilient in terms of participation, albeit with smaller ticket sizes.

The overall trend indicated a more selective investment environment, with sustained interest in mid-market and growth-stage opportunities despite cautious capital deployment.

“Investor focus is clearly shifting toward scalable, capability-led assets, particularly across digital health, specialised care, and consumer health segments. Meanwhile, outbound expansion and portfolio realignment by pharmaceutical companies reflect a strategic pivot toward long-term value creation and global competitiveness,” said Bhanu Prakash Kalmath S.J., Partner and Healthcare Industry Leader, Grant Thornton Bharat.

Domestic transactions continued to dominate in terms of volume in the M & A landscape, the report noted. Deal sizes remained relatively small, with most transactions under $50 million, particularly across hospitals and pharma and biotech segments, pointing to sustained mid-market consolidation driven by regional hospital acquisitions and pharma deals.

Private equity and venture capital activity comprised 45 deals worth $456 million, marking the segment’s highest deal volumes since Q2 2022 and up around 22 per cent rise sequentially.

Investment activity was particularly robust across health tech and wellness segments, including AI-led diagnostics, preventive healthcare, and digital care platforms, highlighting continued interest in scalable, tech-enabled healthcare models.

Early‑stage rounds dominated PE/VC volumes, with pre‑seed to Series A accounting for about 69 per cent of deal volumes and nearly 95 per cent of deals sized below $50 million.

IPO and QIP activity remained selective during the quarter, as one IPO raised $18 million, marking a sharp decline in issuances, and QIP activity picked up modestly with two issuances totalling $500 million.

–IANS

aar/vd

Scientists link type 2 diabetes with some obesity-related cancers

London, March 23 (IANS) A new diagnosis of type 2 diabetes (T2D) has been linked to a subsequent increase in the risk of developing some, but not all, obesity related cancers, according to new research.

Previous research has described associations between type 2 diabetes mellitus and higher risk of several obesity-related cancers.

However, it remains unclear whether these associations are causal, due to confounding (their mutual risk factor of obesity); immortal time bias (many studies combine prevalent and new-onset T2D); or time detection bias (for example, the co-diagnosis of two relatively common conditions at the same time).

In this study, to be presented at European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May), the authors aimed to address these previous methodological flaws.

They performed a matched cohort control study within UK Biobank of new-onset T2D (defined by date of first reported non-insulin dependent diabetes) versus unexposed individuals matched (1 participant to 3 controls) on body mass index (BMI), age, and sex.

A total of 23,750 participants with T2D were matched with 71,123 controls. Over a median follow-up time of 5 years, there were 2431 new primary cancers among T2D participants and 5184 new primary cancers among matched controls.

The data analysis showed new-onset T2D was associated with a 48 per cent increased risk of obesity related cancers in men and a 24 per cent increased risk in women – an effect independent of BMI. However, there were no associations with several site-specific ORCs – notably, endometrial, and post-menopausal breast cancer in women

There were positive associations found – new onset T2D increased the risk for bowel cancer by 27 per cent in men and 34 per cent in women; for pancreatic cancer by 74 per cent in men and a near-doubling of risk in women. For liver cancer new onset T2D was associated with a near-quadrupling of risk in men and near 5-fold increased risk in women.

“At this stage, we are unsure whether these differences in men and women are due to a sex-dependent biological pathway such as hormone levels, insulin sensitivity, body fat composition, or due to a simple difference in the number of cancers found in men and women within UK Biobank by chance,” said the study authors.

—IANS

na/